The formation of the Government of Western Australia is prescribed in its Constitution, which dates from 1890, although it has been amended many times since then. Since 1901 Western Australia has been a state of the Commonwealth of Australia, and the Australian Constitution regulates its relationship with the Commonwealth. Under the Australian Constitution, Western Australia ceded certain legislative and judicial powers to the Commonwealth, but retained complete independence in all other areas. Western Australia is governed according to the principles of the Westminster system, a form of parliamentary government based on the model of the United Kingdom.Legislative power rests with the Parliament of Western Australia, which consists of the Crown, represented by the Governor of Western Australia, and the two Houses, the Western Australian Legislative Council and the Western Australian Legislative Assembly. Executive power rests formally with the Executive Council, which consists of the Governor and senior ministers. In practice executive power is exercised by the Premier of Western Australia and the Cabinet, who are appointed by the Governor, but who hold office by virtue of their ability to command the support of a majority of members of the Legislative Assembly. Judicial power is exercised by the Supreme Court of Western Australia and a system of subordinate courts, but the High Court of Australia has final jurisdiction. Other federal courts also have jurisdiction over certain matters, but only insofar as the Australian Constitution grants the federal government power to make laws for such matters. Wikipedia.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2012.2.1.1-1-C | Award Amount: 17.68M | Year: 2012
Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts have little interoperability and almost no systematic connection between detailed clinical and genetic information, biomaterial availability or research/trial datasets. By developing robust mechanisms and standards for linking and exploiting these data, RD-Connect will develop a critical mass for harmonisation and provide a strong impetus for a global trial-ready infrastructure ready to support the IRDiRC goals for diagnostics and therapies for RD in close collaboration with the successful A/B projects. It will build on and transform the current state-of-the-art across databases, registries, biobanks, bioinformatics, and ethical considerations to develop a quality-assured and comprehensive integrated hub/platform in which complete clinical profiles are combined with -omics data and sample availability for RD research. The integrated, user-friendly RD-Connect platform, built on efficient informatics concepts already implemented in international research infrastructures for large-scale data management, will provide access to federated databases/registries, biobank catalogues, harmonised -omics profiles, and cutting-edge bioinformatics tools for data analysis. All patient data types will be linked via the generation of a unique identifier (RD-ID) developed jointly with the US NIH. The RD-Connect platform will be one of the primary enablers of progress in IRDiRC-funded research and will facilitate gene discovery, diagnosis and therapy development. RD-Connect has the RD field at its heart and brings together partners with a strong track record in RD research (gene discovery and development of innovative treatments), as well as committed IRDiRC funding partners and representatives of all major international RD initiatives (EU/US/AU/JP) spanning patient organisations, research and public health, to maximise impact to RD patients
News Article | November 17, 2016
A brief but brilliant burst of radiation that travelled at least a billion light years through Space to reach an Australian radio telescope last year has given scientists new insight into the fabric of the Universe. ICRAR-Curtin University's Dr Ryan Shannon, who co-led research into the sighting along with the California Institute of Technology's Dr Vikram Ravi, said the flash, known as a Fast Radio Burst (FRB), was one of the brightest seen since FRBs were first detected in 2001. The flash was captured by CSIRO's Parkes radio telescope in New South Wales. Dr Shannon, from the Curtin node of ICRAR (the International Centre for Radio Astronomy Research) and CSIRO, said all FRBs contained crucial information but this FRB, the 18th detected so far, was unique in the amount of information it contained about the cosmic web - the swirling gases and magnetic fields between galaxies. "FRBs are extremely short but intense pulses of radio waves, each only lasting about a millisecond. Some are discovered by accident and no two bursts look the same," Dr Shannon said. "This particular FRB is the first detected to date to contain detailed information about the cosmic web - regarded as the fabric of the Universe - but it is also unique because its travel path can be reconstructed to a precise line of sight and back to an area of space about a billion light years away that contains only a small number of possible home galaxies." Dr Shannon explained that the vast spaces between objects in the Universe contain nearly invisible gas and a plasma of ionised particles that used to be almost impossible to map, until this pulse was detected. "This FRB, like others detected, is thought to originate from outside of Earth's own Milky Way galaxy, which means their signal has travelled over many hundreds of millions of light years, through a medium that - while invisible to our eyes - can be turbulent and affected by magnetic fields," Dr Shannon said. "It is amazing how these very few milliseconds of data can tell how weak the magnetic field is along the travelled path and how the medium is as turbulent as predicted." This particular flash reached CSIRO's Parkes radio telescope mid-last year and was subsequently analysed by a mostly Australian team. A paper describing the FRB and the team's findings was published today in the journal Science. The Parkes telescope has been a prolific discoverer of FRBs, having detected the vast majority of the known population including the very first, the Lorimer burst, in 2001. FRBs remain one of the most mysterious processes in the Universe and likely one of the most energetic ones. To catch more FRBs, astronomers use new technology, such as Parkes' multibeam receiver, the Murchison Widefield Array (MWA) in Western Australia, and the upgraded Molonglo Observatory Synthesis Telescope near Canberra. This particular FRB was found and analysed by a system developed by the supercomputing group led by Professor Matthew Bailes at Swinburne University of Technology. Professor Bailes, who was a co-author on the Science paper, also heads The Dynamic Universe research theme in the ARC Centre of Excellence for All-sky Astrophysics (CAASTRO), which has seven Australian nodes including ICRAR-Curtin University. "Ultimately, FRBs that can be traced to their cosmic host galaxies offer a unique way to probe intergalactic space that allow us to count the bulk of the electrons that inhabit our Universe," Professor Bailes said. "To decode and further understand the information contained in this FRB is an exceptional opportunity to explore the physical forces and the extreme environment out in Space." "The magnetic field and turbulence of the cosmic web measured using a brilliant fast radio burst" published November 17th 2016 in Science. CAASTRO is a collaboration of The University of Sydney, The Australian National University, The University of Melbourne, Swinburne University of Technology, The University of Queensland, The University of Western Australia and Curtin University, the latter two participating together as the International Centre for Radio Astronomy Research (ICRAR). CAASTRO is funded under the Australian Research Council (ARC) Centre of Excellence program, with additional funding from the seven participating universities and from the NSW State Government's Science Leveraging Fund. ICRAR is a joint venture between Curtin University and The University of Western Australia with support and funding from the State Government of Western Australia.CONTACTS
News Article | November 29, 2016
The first available dengue vaccine, CYD-TDV (Dengvaxia), is estimated to reduce the burden of dengue and be potentially cost effective in settings where infections with dengue are common, according to a study published by Stefan Flasche from the London School of Hygiene & Tropical Medicine, UK and an international consortium of dengue experts, in PLOS Medicine. The researchers used dynamical models informed by the results of efficacy trials combined with assumptions on vaccine mechanisms, to estimate the impact and cost-effectiveness of CYD-TDV over a 30-y post-vaccination period in a variety of epidemiological settings. In settings with moderate to high dengue transmission intensity, i.e. where at least 50% of children get infected with dengue before they are nine years old, they estimated that a routine vaccination policy involving a three-dose schedule in 9-y-old children at 80% coverage would reduce the burden of dengue disease for the population by 6%-25% and that vaccination would be potentially cost-effective if priced competitively. However, in settings where dengue infections are uncommon, they identified a risk of potential increase in hospitalizations for dengue disease. These findings were an important contribution to the evidence base that led the WHO to recommend countries to consider the use of CYD-TDV only in settings with a high burden of dengue disease. The authors say: "Our results can guide countries on the general suitability of Dengvaxia introduction; however, local factors related to treatment costs, intensity of dengue transmission and age groups particularly exposed to dengue will need to be considered." In a linked Perspective, Jacqueline Deen from the University of the Philippines, Manila, discusses challenges in balancing the individual and population risks and benefits for CYD-TDV. SF and MJ received funding from WHO and Gavi, the Vaccine Alliance, to conduct this work. LC is a paid employee at Sanofi Pasteur. GM and JK were funded by the University of Western Australia, with computing resources provided by the Pawsey Supercomputing Centre, which is funded by the Australian Government and the Government of Western Australia. MR is funded by a Royal Society University Research Fellowship. NF, ID and DJL received research funding from the UK Medical Research Council, the UK NIHR under the Health Protection Research Unit initiative, NIGMS under the MIDAS initiative, and the Bill and Melinda Gates Foundation. IRB and DATC were funded by MIDAS Center Grant NIH/NIGMS U54-GM088491 and the Bill and Melinda Gates Foundation. DATC was also supported by NIH/NIAID R01-AI114703. TJH, IL, and CABP were funded by a Dengue Vaccine Initiative Grant to IL, NIH/NIAID R37 AI32042. THJ, IL, and KK were funded by MIDAS Center Grant NIH/NIGMS 1135 U54 GM111274. All other authors have received no specific funding to conduct this work. The funders had no role in the study design, data analyses, decision to publish or preparation of the manuscript. I have read the journal's policy and the authors of this manuscript have the following competing interests: LC is employed by Sanofi Pasteur. KV is a staff member of the World Health Organization. TAP and GE receive support from GlaxoSmithKline for unrelated work on dengue vaccine modelling. IL, TJH, and CABP have received travel support from Sanofi Pasteur to present other work on dengue vaccine modelling. Sanofi Pasteur has not funded any of their research and was not involved in any research decisions related to their work presented. NF gave advice to Sanofi-Pasteur and the World Health Organization on the efficacy profile and potential public health impact of Dengvaxia. He is also collaborating with Sanofi-Pasteur on secondary analyses of Dengvaxia clinical trial data. He has received no remuneration, grant income, expense payments or in-kind benefit from Sanofi-Pasteur. DATC and IRB have advised WHO on the use of the Sanofi vaccine in a number of meetings and as part of a consortium of modelers who estimated the potential impact of the vaccine. On occasion they received travel expenses for visits to WHO. They have also advised Sanofi Pasteur Ltd. on the implications their work has for use of their vaccine. They have not received any financial or in-kind payment from Sanofi. All other authors have declared that no competing interests exist. Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, et al. (2016) The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med 13(11): e1002181. doi:10.1371/journal.pmed.1002181 London School of Hygiene and Tropical Medicine, London, United Kingdom Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America Sanofi Pasteur, Brussels, Belgium University of Exeter, Exeter, United Kingdom Duke University, Durham, North Carolina, United States of America University of Western Australia, Crawley, Australia University of Florida, Gainesville, Gainesville, Florida, United States of America University of Notre Dame, Notre Dame, Indiana, United States of America Imperial College London, London, United Kingdom University of Oxford, Oxford, United Kingdom Indiana University, Bloomington, Indiana, United States of America World Health Organization, Geneva, Switzerland IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:http://journals. No funding was received for this work. I have read the journal's policy and have the following conflicts: I was an unpaid external consultant in the "Extended Study Group for dengue vaccine effectiveness evaluation studies in Asia" from 6 April 2015 to 31 August 2015 convened by Sanofi Pasteur. I was a WHO temporary adviser in a meeting entitled "Targeting Vaccination and Post-licensure Studies for the Licensed Dengue Vaccine" in Geneva from 14 to 15 June 2016 convened by the WHO. I am an unpaid co-investigator of a study entitled "Effectiveness of the tetravalent dengue vaccine, CYD-TDV (Dengvaxia) in the Philippines" currently in preparation, sponsored by the University of the Philippines-Manila and funded by Sanofi Pasteur. Deen J (2016) The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits. PLoS Med 13(11): e1002182. doi:10.1371/journal.pmed.1002182 Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines, Manila, Philippines IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:http://journals.
News Article | February 17, 2017
A minor planet in the Solar System will officially be known as Bernardbowen from today after Australian citizen science project theSkyNet won a competition to name the celestial body. The minor planet was named by the International Centre for Radio Astronomy Research (ICRAR) in honour of their founding chairman Dr Bernard Bowen. Bernardbowen sits in the asteroid belt between Mars and Jupiter and takes 3.26 Earth years to orbit the Sun. The minor planet was discovered on October 28, 1991, and until now has been known as (6196) 1991 UO4. Based at ICRAR, theSkyNet has been running since 2011 and sees citizen scientists donating their spare computing power to help Australian astronomers uncover the mysteries of the Universe. Its 50,000-odd volunteers entered an International Astronomical Union (IAU) contest to name planets beyond our Solar System. Project founders ICRAR also won the right to name a minor planet within our Solar System. Bernardbowen was one of 17 minor planets to be christened today. Other newly named minor planets include Kagura, after a traditional Shinto theatrical dance, and Mehdia, which is equivalent to the Arabic word for gift. Dr Bowen is renowned as one of the country's finest science administrators and has presided over scientific advances ranging from the oceans to the skies. He was instrumental in the establishment of ICRAR in 2009, and helped bring part of the Square Kilometre Array telescope to Western Australia. A full list of the citation of the minor planets can be found at the IAU Minor Planet Circular. http://bit. Bernardbowen on the Minor Planet Centre site, including an interactive showing its position in the Solar System. http://bit. Images of the orbit of minor planet Bernardbowenare available at http://www. A minor planet is an astronomical object in direct orbit around the Sun that is neither a planet nor exclusively classified as a comet. Minor planets can be dwarf planets, asteroids, trojans, centaurs, Kuiper belt objects, and other trans-Neptunian objects. The International Centre for Radio Astronomy Research (ICRAR) is a joint venture between Curtin University and The University of Western Australia with support and funding from the State Government of Western Australia. http://www. By connecting 100s and 1000s of computers together through the Internet, it's possible to simulate a single machine capable of doing some pretty amazing stuff. That's what theSkyNet is all about - using your spare computing power to process radio astronomy data. http://www. The IAU is the international astronomical organisation that brings together more than 10 000 professional astronomers from almost 100 countries. Its mission is to promote and safeguard the science of astronomy in all its aspects through international cooperation. The IAU also serves as the internationally recognised authority for assigning designations to celestial bodies and the surface features on them. Founded in 1919, the IAU is the world's largest professional body for astronomers. http://www.
News Article | October 27, 2016
A telescope located deep in the West Australian outback has shown what the Universe would look like if human eyes could see radio waves. Published today in the Monthly Notices of the Royal Astronomical Society, the GaLactic and Extragalactic All-sky MWA, or 'GLEAM' survey, has produced a catalogue of 300,000 galaxies observed by the Murchison Widefield Array (MWA), a $50 million radio telescope located at a remote site northeast of Geraldton. Lead author Dr Natasha Hurley-Walker, from Curtin University and the International Centre for Radio Astronomy Research (ICRAR), said this is the first radio survey to image the sky in such amazing technicolour. "The human eye sees by comparing brightness in three different primary colours - red, green and blue," Dr Hurley-Walker said. "GLEAM does rather better than that, viewing the sky in 20 primary colours. "That's much better than we humans can manage, and it even beats the very best in the animal kingdom, the mantis shrimp, which can see 12 different primary colours," she said. GLEAM is a large-scale, high-resolution survey of the radio sky observed at frequencies from 70 to 230 MHz, observing radio waves that have been travelling through space--some for billions of years. "Our team are using this survey to find out what happens when clusters of galaxies collide," Dr Hurley-Walker said. "We're also able to see the remnants of explosions from the most ancient stars in our galaxy, and find the first and last gasps of supermassive black holes." MWA Director Associate Professor Randall Wayth, from Curtin University and ICRAR, said GLEAM is one of the biggest radio surveys of the sky ever assembled. "The area surveyed is enormous," he said. "Large sky surveys like this are extremely valuable to scientists and they're used across many areas of astrophysics, often in ways the original researchers could never have imagined," Associate Professor Wayth said. Completing the GLEAM survey with the MWA is a big step on the path to SKA-low, the low frequency part of the international Square Kilometre Array (SKA) radio telescope to be built in Australia in the coming years. "It's a significant achievement for the MWA telescope and the team of researchers that have worked on the GLEAM survey," Associate Professor Wayth said. "The survey gives us a glimpse of the Universe that SKA-low will be probing once it's built. By mapping the sky in this way we can help fine-tune the design for the SKA and prepare for even deeper observations into the distant Universe." 'GaLactic and Extragalactic All-sky Murchison Widefield Array (GLEAM) survey I: A low-frequency extragalactic catalogue', published in the Monthly Notices of the Royal Astronomical Society on October 27th, 2016. The Murchison Widefield Array (MWA) is a low frequency radio telescope located at the Murchison Radio-astronomy Observatory in Western Australia's Mid West. The MWA observes radio waves with frequencies between 70 and 320 MHz and was the first of the three Square Kilometre Array (SKA) precursors to be completed. A consortium of 13 partner institutions from four countries (Australia, USA, India and New Zealand) has financed the development, construction, commissioning and operations of the facility. Since commencing operations in mid 2013 the consortium has grown to include new partners from Canada and Japan. Key science for the MWA ranges from the search for redshifted HI signals from the Epoch of Reionisation to wide-field searches for transient and variable objects (including pulsars and Fast Radio Bursts), wide-field Galactic and extra-galactic surveys, and solar and heliospheric science. The Square Kilometre Array (SKA) project is an international effort to build the world's largest radio telescope, led by SKA Organisation based at the Jodrell Bank Observatory near Manchester, England. Co-located primarily in South Africa and Western Australia, the SKA will be a collection of hundreds of thousands of radio antennas with a combined collecting area equivalent to approximately one million square metres, or one square kilometre. The SKA will conduct transformational science to improve our understanding of the Universe and the laws of fundamental physics, monitoring the sky in unprecedented detail and mapping it hundreds of times faster than any current facility. The International Centre for Radio Astronomy Research (ICRAR) is a joint venture between Curtin University and The University of Western Australia with support and funding from the State Government of Western Australia. High-resolution videos and imagery are available from http://www. (password = 'glimmer').
News Article | February 15, 2017
OLDSMAR, Fla.--(BUSINESS WIRE)--TouchPoint Medical (TouchPoint), a leading global provider of innovative and intelligent hardware and software solutions for healthcare, announced today that TouchPoint’s solutions have been implemented by Fiona Stanley Hospital as the mobile medication transport and mobile workstation component of its Closed-Loop Medication Management System. Fiona Stanley Hospital’s medication management and delivery workflow is the best-practice model for all of the Government of Western Australia’s Department of Health facilities. Ranked among the best in Australia, Fiona Stanley Hospital is a 783-bed, $2 billion public hospital. In addition to delivering comprehensive clinical services, Fiona Stanley Hospital is a leader in research and education. Its medical equipment and state-of-the-art information and communications technology rank as the most advanced in the Asia Pacific region. FSH has selected TouchPoint’s all-new next generation mobile computing solution for the system’s advanced ergonomic design, integrated medication tracking and support and industry-leading configurability. TouchPoint’s solutions at Fiona Stanley Hospital include the AccessRx MD Mobile Medication Management System, powered by the Applied PilotFish Healthcare Integration (PilotFish) HL7 Interface Engine, TouchPoint’s Medication Management solution offers the flexible integration options and architecture needed to ensure long-term support for any future technology requirements. “TouchPoint brings together an outstanding team and resources throughout the world with the passion to dramatically improve the environment and experience for both healthcare professionals and their patients,” said Fouad Abu-Akel, Director, Technical Applications, TouchPoint. “With the PilotFish HL7 Interface Engine, TouchPoint’s AccessRx MD Mobile Medication Management System seamlessly integrates into Fiona Stanley Hospital’s workflows and Closed-Loop Medication Management System. We are honored to be selected as a partner at Fiona Stanley Hospital, the lynchpin in the total rebuild of Western Australia’s health system.” TouchPoint’s AccessPoint Rx MD Mobile Medication Management System is designed from the bottom up to be scalable, easy to service and highly adaptable to future technology upgrades. The user is paramount, with ergonomic features designed to support ease-of-use, efficiency and reduced hospital costs. TouchPoint designed the system to work not only with its own products, but also with those of other vendors, giving hospitals more options now and in the future. “PilotFish is thrilled to be a significant enabling technology partner with TouchPoint in contributing to Fiona Stanley Hospital’s role as a world-leading digital hospital and in supporting WA Health systems,” said Monika Vainius, Executive Vice President at PilotFish. “The PilotFish HL7 Interface Engine offers the advanced technology, automated processes, flexibility and rapid development tools needed to effectively integrate with the ever-evolving array of IT systems and equipment found in world-class hospitals.” Innovation and models of best practice are at the core of Healthcare Information and Communication Technology in Australia and at Fiona Stanley Hospital. TouchPoint and PilotFish are committed to help rapidly bring those advances to the bedside and beyond in the mission to improve patient care and public health. TouchPoint is a privately held, diversified global growth company based in Concordville, PA. TouchPoint focuses on acquiring and building niche, high-growth manufacturing businesses where technology and human touch points make a tangible difference to the end user. In total, TouchPoint companies have over 3,600 employees in 24 countries and serve in excess of 80,000 customers in nearly 100 countries throughout the world. For more information, please visit www.touchpointmed.com. APHI is a subsidiary of PilotFish Technology. Founded in 2001 and based in Middletown, Conn. PilotFish develops middleware to enable the integration of disparate systems. APHII distributes PilotFish products directly to healthcare industry end users, solution providers and through select channel partners. Visit www.healthcare.pilotfishtechnology.com for more information.
Kilminster K.,Government of Western Australia
Marine Pollution Bulletin | Year: 2013
Estuarine environments are particularly vulnerable to human impacts. In this study, trace elements in Ruppia megacarpa, Halophila ovalis, sediment and porewater were analysed to assess the potential contamination of the Leschenault Estuary, Western Australia, from a primarily agricultural drain. Sediment concentrations of Cd, Cu, Mn, and Ni and were highest nearest the drain while Al, As, Cr, Fe and Zn and were highest further from the drain. H. ovalis showed greater accumulation of Fe, Al, and As than R. megacarpa. Concentrations of Fe, Al, As, and Ni were generally higher in below-ground plant parts than above, suggesting uptake of these trace elements via the sediment-route pathway. This study suggested that the drain was a source of Cu and Mn, with these elements entering the estuary through water inflows. As and Fe, were highest furthest from the drain suggesting input of trace elements from sources other than the drain under study. © 2013 Elsevier Ltd.
Wakefield C.B.,Government of Western Australia
Journal of Fish Biology | Year: 2010
Ichthyoplankton sampling and ovarian characteristics were used to elucidate whether the reproductive cycles of a spawning aggregation of snapper Pagrus auratus in a nearshore marine embayment were temporally and spatially specific and related with environmental conditions. The reproductive dynamics of this aggregation were studied over four consecutive years (2001-2004.Spawning occurred between September and January each year, when water temperatures ranged from 15·8 to 23·1° C. In all 4 years, the cumulative egg densities in Cockburn Sound were highest when water temperatures were between the narrow range of 19-20° C. The spawning fraction of females was monthly bimodal and peaked during new and the full moons at 96-100% and c. 75%, respectively. The backcalculated ages of P. auratus eggs collected from 16 ichthyoplankton surveys demonstrated that P. auratus in Cockburn Sound spawn at night during the 3 h following the high tide. The spatial distributions of P. auratus eggs in Cockburn Sound during the peak reproductive period in all 4 years were consistent, further implying spawning was temporally and spatially specific. High concentrations of recently spawned eggs (8-16 h old) demonstrated spawning also occurred within the adjacent marine embayments of Owen Anchorage and Warnbro Sound. Water circulation in Cockburn and Warnbro Sounds resembled an eddy that was most prominent during the period of highest egg densities, thereby facilitating the retention of eggs in these areas. The reproductive cycles of P. auratus described in this study have assisted managers with the appropriate temporal and spatial scale for a closed fishing season to protect these spawning aggregations. ©2010 The Fisheries Society of the British Isles.
Jones B.,Government of Western Australia
Journal of Invertebrate Pathology | Year: 2012
Shrimp and shrimp products form the most valuable internationally traded fisheries commodity, and the volumes are huge, estimated to be about 3.6 million tonnes. However, despite the existence under the General Agreement on Tariffs and Trade, of the Sanitary and Phytosanitary Measures (SPS Agreement) and the activities of the World Organisation for Animal Health (OIE), viral shrimp epizootics have spread and continue to spread, affecting world production. Though most attention has focussed on the movement of live shrimp product, the spread of new and emerging diseases through other crustaceans and their nonviable products is of increasing concern. The risks associated with the unrestricted movement of nonviable product will be outlined and measures that can be taken to mitigate the risk are discussed. Ultimately, for crustacean diseases, the paradigm under which the OIE has operated for the past 80. years needs to change. © 2012.
News Article | October 25, 2016
BP Australia has agreed to renew its State Agreement with the Government of Western Australia for a further 30 years.